Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;36(1):59-66.
doi: 10.1002/jca.21840. Epub 2020 Sep 17.

Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology

Fernando Andrés Chuliber  1 , Diana Penchasky  1 , Diego Mario Santoro  2 , Susana Viñuales  1 , Victoria Otero  1 , Maximiliano Villagra Iturre  1 , Verónica Privitera  1 , Daniela Mezzarobba  1 , Leandro Burgos Pratx  2 , Marina Sol López  3 , Luis Barrera  3 , Natalia Schutz  1 , Jorge Arbelbide  1 , Marta Martinuzzo  3
Affiliations

Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology

Fernando Andrés Chuliber et al. J Clin Apher. 2021 Feb.

Abstract

Introduction: Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency.

Objectives: To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE.

Methods: We respectively studied a cohort of consecutive patients from 2014 to 2019 who were treated with TPE with FXIII levels <50%. The FXIII was measured after the start of the TPE course, on days between the TPE sessions, due to suspected acquired deficiency. All TPE were performed using continuous flow cell separator. In all cases, the initial replacement fluid applied was albumin. Apheresis procedures were held at 24to 48 hours intervals.

Results: Eighteen patients were included, 13 of them were recipients of kidney transplants. The main TPE prescription was humoral rejection. Median FXIII at diagnosis (measured on days between sessions of the TPE course) was 19%(IQR17-25). The median of apheresis procedures before measurement of FXIII was 3(IQR2-4). Among the total cohort, 10 patients suffered hemorrhages. None of the patients without history of kidney transplants had bleeding (n = 5), however, 10/13 with kidney transplants did. Five kidney transplant patients received therapy with FXIII concentrate because of life-threatening bleeding. In all cases, the bleeding stopped within the first 24 hours. All patients had their FXIII levels measured again after finishing the TPE course, with normal results.

Conclusions: TPE is an under-diagnosed cause of acquired FXIII deficiency since routine coagulation tests remain unaltered. It might cause major bleeding, particularly in patients with a recent history of surgery like kidney transplants.

Keywords: bleeding; factor XIII; factor XIII deficiency; kidney transplants; therapeutic plasma exchange.

PubMed Disclaimer

References

REFERENCES

    1. Kohler HP, Ichinose A, Seitz R, Ariens R, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9:1404-1406.
    1. Karimi M, Peyvandi F, Naderi M, Shapiro A. Factor XIII deficiency diagnosis: Challenges and tools. Int J Lab Hem. 2018;40:3-11.
    1. Komaromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost. 2011;9:9-20.
    1. Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: A coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931-972.
    1. Katona E, Pénzes K, Csapó A, et al. Interaction of factor XIII subunits. Blood. 2014;123:1757-1763.

LinkOut - more resources